Credit Suisse Group Reiterates “€85.00” Price Target for Merck KGaA (MRK)

Share on StockTwits

Credit Suisse Group set a €85.00 ($98.84) price objective on Merck KGaA (FRA:MRK) in a research report sent to investors on Wednesday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other analysts also recently weighed in on MRK. Berenberg Bank set a €104.00 ($120.93) target price on Merck KGaA and gave the company a buy rating in a report on Wednesday. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the company a buy rating in a report on Tuesday. Warburg Research set a €105.00 ($122.09) target price on Merck KGaA and gave the company a buy rating in a report on Tuesday. Societe Generale set a €88.00 ($102.33) target price on Merck KGaA and gave the company a neutral rating in a report on Wednesday. Finally, Goldman Sachs Group set a €92.00 ($106.98) target price on Merck KGaA and gave the company a neutral rating in a report on Tuesday. Eleven analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Merck KGaA currently has a consensus rating of Buy and an average target price of €99.86 ($116.12).

Merck KGaA opened at €85.00 ($98.84) on Wednesday, MarketBeat reports. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply